HIKMA PHARMACEUTIC.LS-,10/ GB00B0LCW083 /
| 2024-05-23 10:53:57 PM | Chg. +0.200 | Volume | Bid10:53:57 PM | Ask10:53:57 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 22.800EUR | +0.88% | - Turnover: - |
22.800Bid Size: - | 23.200Ask Size: - | 5.1 bill.EUR | - | - |
Assets
| 2018 IFRS in mill. USD |
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 870 | 912 | 1,009 | 1,146 | 1,081 | ||||||
| Intangible Assets | 487 | 552 | 587 | 607 | 735 | ||||||
| Long-Term Investments | 68 | 43 | 48 | - | - | ||||||
| Fixed Assets | 1,829 | 2,082 | 2,213 | 2,278 | 2,472 | ||||||
| Inventories | 528 | 568 | 757 | 695 | 776 | ||||||
| Accounts Receivable | 731 | 719 | 756 | 816 | 809 | ||||||
| Cash and Cash Equivalents | 276 | 442 | 323 | 426 | 270 | ||||||
| Current Assets | 1,668 | 1,848 | 1,922 | 2,094 | 1,999 | ||||||
| Total Assets | 3,497 | 3,930 | 4,135 | 4,372 | 4,471 | ||||||
Liabilities
| 2018 IFRS in mill. USD |
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 465 | 473 | 470 | 468 | 476 | ||||||
| Long-term debt | 539 | 48 | 692 | 725 | 1,135 | ||||||
| Liabilities to Banks | 613 | 617 | 850 | - | - | ||||||
| Provisions | 39 | 43 | 59 | 55 | 51 | ||||||
| Liabilities | 1,800 | 1,801 | 1,987 | 1,905 | 2,323 | ||||||
| Share Capital | 40 | 41 | 41 | - | - | ||||||
| Total Equity | 1,685 | 2,117 | 2,135 | 2,453 | 2,135 | ||||||
| Minority Interests | 12 | 12 | 13 | 14 | 13 | ||||||
| Total liabilities equity | 3,497 | 3,930 | 4,135 | 4,372 | 4,471 | ||||||
Income Statement
| 2018 IFRS in mill. USD |
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 2,070 | 2,207 | 2,341 | 2,553 | 2,517 | ||||||
| Depreciation (total) | - | - | 2 | - | - | ||||||
| Operating Result | 371 | 493 | 579 | 582 | 282 | ||||||
| Interest Income | - | - | - | -39 | -52 | ||||||
| Income Before Taxes | 293 | 491 | 558 | - | - | ||||||
| Income Taxes | -8 | -4 | -128 | 124 | 42 | ||||||
| Minority Interests Profit | -4 | -1 | 1 | 1 | -3 | ||||||
| Net Income | 282 | 486 | 431 | 421 | 188 | ||||||
Per Share
Cash Flow
| 2018 IFRS in mill. USD |
2019 IFRS in mill. USD |
2020 IFRS in mill. USD |
2021 IFRS in mill. USD |
2022 IFRS in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 430 | 472 | 464 | 638 | 530 | ||||||
| Cash Flow from Investing Activities | -96 | -151 | -283 | -238 | -607 | ||||||
| Cash Flow from Financing | -278 | -155 | -298 | -287 | -58 | ||||||
| Decrease / Increase in Cash | 56 | 166 | -117 | - | - | ||||||
| Employees | 8,413 | 8,578 | 8,681 | 8,703 | 8,835 | ||||||
